Codexis, Inc. (CDXS) |
| 2.43 -0.13 (-5.08%) 07-10 16:00 |
| Open: | 2.56 |
| High: | 2.57 |
| Low: | 2.37 |
| Volume: | 547,006 |
| Market Cap: | 221(M) |
| PE Ratio: | -6.57 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 2.91 |
| Resistance 1: | 2.63 |
| Pivot price: | 2.44 |
| Support 1: | 2.17 |
| Support 2: | 1.81 |
| 52w High: | 3.87 |
| 52w Low: | 0.96 |
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
| EPS | -0.350 |
| Book Value | 0.480 |
| PEG Ratio | 13.53 |
| Gross Profit | 0.205 |
| Profit Margin (%) | -40.96 |
| Operating Margin (%) | -52.75 |
| Return on Assets (ttm) | -12.5 |
| Return on Equity (ttm) | -68.9 |
Sat, 04 Jul 2026
Price to earnings forward of Codexis, Inc. – NASDAQ:CDXS - TradingView
Sat, 27 Jun 2026
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results - 富途牛牛
Thu, 25 Jun 2026
CDXS Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 22 Jun 2026
Codexis (CDXS) shareholders back board nominees, KPMG and pay plan - Stock Titan
Thu, 18 Jun 2026
Codexis (CDXS) director David V. Smith granted 66,350 stock options at $2.48 - Stock Titan
Mon, 11 May 2026
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results - simplywall.st
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |